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Abstract
Bone morphogenetic protein receptor type 2 (BMPR2) mutations are present in patients with heritable and idiopathic pulmonary
arterial hypertension (PAH). Circulating levels of interleukin-1 (IL-1) are raised in patients and animal models. Whether interplay
between BMP and IL-1 signaling can explain the local manifestation of PAH in the lung remains unclear. Cell culture, siRNA, and
mRNA microarray analysis of RNA isolated from human pulmonary artery (PASMC) and aortic (AoSMC) smooth muscle cells
were used. R899Xþ/– BMPR2 transgenic mice fed a Western diet for six weeks were given daily injections of IL-1ß prior to
assessment for PAH and tissue collection. PASMC have reduced inflammatory activation in response to IL-1ß compared with
AoSMCs; however, PASMC with reduced BMPR2 demonstrated an exaggerated response. Mice treated with IL-1ß had higher
white blood cell counts and significantly raised serum protein levels of IL-6 and osteoprotegerin (OPG) plasma levels recapitulating
in vitro data. Phenotypically, IL-1ß treated mice demonstrated increased pulmonary vascular remodeling. IL-1ß induces an exag-
gerated pulmonary artery specific transcriptomic inflammatory response when BMPR2 signaling is reduced.
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Pulmonary arterial hypertension (PAH) is driven by vaso-
constriction, inflammatory cell infiltration, vascular cell
migration, proliferation, and apoptosis.1 Molecular mech-
anisms regulating PAH pathogenesis are multifactorial
involving potassium channels, genetic mutations, serotonin
imbalances, estradiol changes, and inflammatory alterations
among others.2,3
Vascular remodeling in PAH is confined to the lung and
patients with the disease do not exhibit alterations in sys-
temic blood pressure or peripheral vascular pathology.4 This
observation indicates that inherent differences in the cellular
behavior in the vascular beds could potentially be one of the
possible reasons why global BMPR2 changes only lead
to pathogenic remodeling of the pulmonary vasculature
while the systemic vessels remain unaltered.
BMPR2 mutations are the primary genetic risk for PAH
implicated in over 70% of heritable and 25% of sporadic
cases; however, disease penetrance even within families is
low (around 15%).5 Inflammatory diseases are associated
with PAH, and levels of the pro-inflammatory cytokine
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interleukins (IL)1/6 are increased in PAH.6 IL-6 over-
expression in vascular cells is enough to induce pulmonary
vessel remodeling and PAH in a rodent model.7
Inflammation has been shown to be increased in patients
and a link with BMPR2 deficiency has been considered.8
Previous animal studies have demonstrated that monocrota-
line (MCT)-induced PAH is prevented by administration of
IL-1 receptor antagonist9 and that Apolipoprotein-E knock-
out mice develop PAH in an IL-1 dependent manner, and
via a lung specific putative IL-1R1 receptor.10 Interestingly,
recent data demonstrated that mice with a heterozygous
mutation in BMPR2 have an increased inflammatory
response to Lipopolysaccharide.11 Further recent literature
indicates that the IL1R1/MyD88 signaling pathway is crit-
ical to development of animal models of PAH.12 We there-
fore hypothesized that under conditions of reduced BMPR2
expression/signaling, IL-1ß can act as a pulmonary-specific
disease-modifying secondary stimulus, thereby demonstrat-
ing a direct link between IL-1ß, BMPR2, and disease
pathogenesis.
Methods
Smooth muscle cell culture and transfection
Human pulmonary artery (hPASMC) (Lonza CC-2581)
from three commercial donors and four primary donors,
including those with and without disease-related BMPR2
mutations, and human aortic smooth muscle cells
(hAoSMC) (Lonza CC-2571) from two donors were main-
tained in smooth muscle cell media SmGM-2 including
bullet kit supplements (Lonza CC-3182). All experiments
were performed between passages 4 and 8. Quiescent
media (Dulbecco’s modified Eagles medium (Lonza
12-604) with 0.2% (v/v) fetal bovine serum ((FBS) Lonza
14-401) was added for 48 h prior to transfection with
siRNA/reporter plasmid (Qiagen Cignal NFkB luciferase
reporter) and/or 6-h stimulation with IL-1ß at 10 ng/mL
or BMP4 at 20 ng/mL.13,14
RNA extraction
RNA was isolated using Trizol, Direct-zol RNA mini prep
kits (Zymo research R2050), and Zymospin column as per
manufacturer’s instructions. Eluted RNA quality was
assessed using the Agilent Bioanalyzer 2100.
Microarray and bioinformatic analysis
Three sample RNA pools were run per sub-array with three
individual RNA pool sub-arrays per condition. Agilent
microarray was performed (Agilent 5190-2305, 5188-5282,
5188-5242, 5188-5327, and RNeasy mini kit, Qiagen 74104)
following the labeling protocol (version 6.6, September 2012
Agilent Technologies, G4140-90040) per manufacturer’s
instructions and scanned using the Agilent G2565BA
scanner.
Data analysis was performed using the Bioconductor
package Limma in the programing language ‘‘R.’’ Target
files were created containing Agilent G2565BA microarray
scanner output files. Background correction, cyclic loess
normalization, and averaging of repeats was performed.
A linear modeling matrix was built and fitted. Gene lists
were filtered discarding those unaltered by IL-1ß in the
order of a log2 fold-change of< 1 and for an adjusted
P value of< 0.05. A pathway analysis functional output
was obtained using Signaling Pathway Impact Analysis
(SPIA) in R. All was as described in previous papers from
our group.13 A two-dimensional projection of the micro-
array expression data was generated using the non-
parametric dimensionality reduction. This was achieved
using the t-distributed stochastic neighbor embedding
(t-SNE) algorithm in the R package Rtse. The resulting
t-SNE output was plotted with R package ggplot2. The
array data will be deposited in NCBI’s Gene Expression
Omnibus.
Luciferase reporter assay
Following 48 h of incubation with siRNA, reporter plasmid,
and stimulants, cells were lysed. Firefly and renila luciferase
were read using Promega dual glo assay as per manufac-
turer’s instructions using a Varioskan Plate reader.
Real-time polymerase chain reaction
of cellular mRNA samples
RNA (n¼ 9–17 for each condition) was reverse transcribed
to cDNA using RNA to cDNA kit (Applied Biosystems
4387406). TaqMan probes for BMPR2 Hs00176148, IL-6
Hs1075666, SOD2 Hs00167309, OPG Hs00917067, VIPR1
Hs00910453 were purchased from Thermo Fisher and run in
duplicate. Human ribosomal 18S Hs99999901 was used as
control. Relative quantity was calculated using the Ct
method.15
Animal models
Rosa26-rtTA2TetO7-Bmpr2R899X mice (called Rosa26-
Bmpr2R899X) were used with mutant expression induced
by doxycycline as previously described.16 Twenty-four
Rosa26-Bmpr2R899X transgenic mice and 12 C57 wild-
type littermates were fed a Western diet for six weeks and
injected with IL-1ß or placebo i.p. once daily for the final
four weeks. Mice were assessed for inflammatory activation
and PAH phenotype as previously described.17 Following
six weeks of treatment, the mice were given injectable
anesthesia for terminal surgery. Animals underwent full
hemodynamic phenotyping, including echocardiography,
right and left heart catheterization, blood sampling
Pulmonary Circulation Volume 7 Number 4 | 769
by cardiac puncture, and a full range of tissues taken
and snap frozen. All animal studies were pre-approved
by Vanderbilt University Institutional Animal Care and
Use Committee.
Enzyme-linked immunosorbent assay
Mouse serum samples were run using assay DY805 (OPG)
and DY206 (IL-6) as per manufacturer’s instructions.
Results
IL-1ß stimulation and BMPR2 dysfunction elicit
vascular bed-specific transcriptional regulation
in smooth muscle cells
PAH is a pulmonary arterial-specific disease suggesting
that there may be vascular bed-specific transcriptional
regulation. A major portion of the vascular disease path-
ology within the lesions is driven by the proliferation and
migration of alpha smooth muscle actin (SMA) positive
cells and we therefore sought to characterize and compare
the cellular signaling profile in smooth muscle actin posi-
tive cells from the pulmonary and aortic smooth muscle
cells (PASMC and AoSMC, respectively). In total, 1235
genes were significantly differentially expressed across
both cell types in response to IL-ß: 444 in PASMC con-
trasting with 919 in AoSMCs. Of these genes, 128 overlap
in both cell types (Fig. 1a). Subsequent SPIA identified
significant differences in the pathways represented by the
genes specific to each cell type (SPIA graphs and tables for
the genes specific to PA and Ao as Supplemental Fig. 1a
and 1b, respectively). Comparison of the altered PASMC
pathways highlighted differences in disease relevant pro-
migratory and pro-proliferative pathways. ‘‘Pathways in
Cancer’’ and infectious disease pathways were altered con-
taining disease-relevant wnt, FADD, and MEK signaling.
These pathways were activated in the AoSMC cells, but
responses were either inhibited or suppressed in the
PASMC (Fig. 1b).
Microarray validation using repeat and separate donor
cells was performed by quantitative reverse transcription
polymerase chain reaction (qRT-PCR) on selected path-
way and disease-relevant genes.13 AoSMC demonstrated
greater increases in inflammatory genes than PASMC
given the same stimulus. All genes analyzed validated
array findings in terms of increase or decrease of gene
expression, although the degree of alteration varied
between platforms. Inflammatory and pro-apoptotic
genes, including IL-6 and OPG, are increased in AoSMC
to a larger extent than PASMC. However, PASMC
demonstrated an increased baseline level of VIPR1 com-
pared to AoSMC but lost expression when stimulated with
IL-1ß. Disease-relevant receptors were also measured.
There were no changes to IL-1ß in PDGF receptors
a or b (Fig. 1c).
BMPR2 deficiency exaggerates inflammatory activation
to IL-1ß stimulation in PASMC but not AoSMC
The BMP and IL-1ß signaling pathways are linked through
the co-localization and co-expression of gene family mem-
bers (http://www.genemania.com, Supplemental Fig. 2),
although the direct influence of one upon the other in
PASMC is unknown. We sought to determine the effect of
reduced BMPR2 expression in PASMCs using siRNA, and
alterations induced by subsequent stimulation with IL-1ß,
using whole-genome microarray. Knock-down of BMPR2
was confirmed by RT-PCR (Fig. 2a). Stimulation with
IL-1ß resulted in the differential expression of 825 genes
on the background of reduced BMPR2 expression com-
pared to 524 in control non-targeting (Ntsi) siRNA-treated
cells (Fig. 2b). SPIA highlighted changes in pathway activa-
tion in ‘‘pathways in cancer’’ and ‘‘rheumatoid arthritis’’
(SPIA graphs and tables for the genes specific to PA with
and without functional BMPR2 as Supplemental Fig. 2a
and 2b, respectively). Overall, there were significant
increases in the pro-inflammatory, pro-proliferative, and
migratory pathways activated, most notably the massive
increased activation of the cytokine and chemokine signal-
ing pathways after IL-1ß stimulation in PASMCs where
BMPR2 expression is reduced (Fig. 2c). This is reflected in
the t-SNE analysis showing that the microarray data clus-
ters into the conditions. In non-targeting silencing RNA-
treated PASMC, the IL-1ß makes an alteration in clustering;
however, this alteration is exaggerated in the presence on
BMPR2 silencing RNA (Fig. 2d).
For further evidence of interactions between the two
pathways, NFkB reporter plasmid (Qiagen Cignal NFkB
luc reporter assay) was used to assess the changes in IL-1ß
signaling through NFkB in the presence and absence of
BMP pathway activation. These experiments showed that
activation of the BMP signaling pathway by stimulation
with BMP4 repressed IL-1ß stimulation of NFkB; however,
upon reduction of BMP signaling through the addition of
silencing RNA to BMPR2, this NFkB signaling was
restored (Fig. 2e).
To consider the effects of reduced BMPR2 expression in
PASMC, validation was performed on PASMC with and
without transfection using silencing RNA to BMPR2.
A small panel of genes was put together from a disease
relevant gene list13 to validate the microarray data that
would cover the range expression changes observed.
Minimal transcriptional changes were noted in the mock
transfection samples (data not shown); however, reduced
BMPR2 expression combined with IL-1ß stimulation
caused a further increase in expression of the pro-inflamma-
tory genes within the panel. This is not the case in AoSMC
with many genes being decreased upon reduced BMPR2
expression, a summary of all the TaqMan carried out has
been included (Fig. 3a).
At the individual gene level, IL-1ß stimulation in condi-
tions of reduced BMPR2 expression in PASMC resulted in a
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greater induction of IL-6 compared to normal BMPR2
expression in PASMC. Using the same regime, there was
no change in IL-6 in aortic cells or in PASMC taken
from donors with and without known BMPR2 mutations
(Fig. 3b). Loss of BMPR2 also caused large increases in the
expression of OPG regardless of IL-1 ß stimulation in
PASMC, but gave rise to a decrease of OPG in unstimulated
aortic cells which was reversed by IL-1ß stimulation,
Fig. 1. Microarray analysis identifies tissue bed specific changes in of IL-1ß transcriptome. mRNA expression patterns in PASMC and AoSMC
(n¼ 9) (a). Changes in mRNA showing a log2 fold-change of> 1 with false discovery rate (FDR)-adjusted P value 0.05. Pathway analysis was
performed using signaling pathway impact analysis (SPIA) pathway analysis software on IL-1ß stimulated in PASMC by using the SPIA package in
Limma using programming language R; all gene information from the PASMC arrays are taken into account and cross-referenced against known
pathways. Altered pathways discovered using SPIA with significant changes to IL-1ß stimulation in PASMC were compared with the AoMSC IL-1ß
responsive pathways changes to generate heatmaps indicating their activation or inhibition in each cell type (b). qRT-PCR validation was
performed in PASMC and AoSMC showing increased expression of inflammatory proteins IL-6 and OPG being more pronounced in AoSMC than
PASMC; PASMC have a sevenfold higher baseline level of VIPR1 which is reduced to IL-1ß. Receptors also showed PDGF receptors a and b being
unaltered to IL-1ß in either cell type. (c) Ordinary one-way ANOVA with multiple comparison by Tukey’s post-test (*P< 0.05, **P< 0.01,
***P< 0.001, ****P< 0.0001).
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in donor cells increases were seen in OPG to IL-1ß stimula-
tion regardless of their mutation status (Fig. 3c). VIPR1 in
aortic cells is unaffected by loss of BMPR2 function; how-
ever, PASMC showed a significant increase at baseline
which was normalized by IL-1ß. PASMC taken from
donors display the same pattern as commercial PASMC,
where loss of BMPR2 function induces a large increase in
VIPR1 expression which can be normalized to an extent by
IL-1ß (Fig. 3d).
Array validation by qRT-PCR of receptor expression
showed that expression of PDGF receptors in PAMSC
increased to loss of BMPR2 expression but normalized
Fig. 2. Microarray investigation in PASMC identifies BMPR2 specific changes in IL-1ß transcriptome. qRT-PCR was performed on pooled samples
to confirm knockdown prior to arrays (n¼ 6 for BMPR2si and 3 for NTSi) (a). mRNA expression patterns in PASMC þ/– BMPR2 siRNA (n¼ 9).
Ordinary one-way ANOVA with multiple comparisons by Tukey’s post-test (****P< 0.0001). Changes in mRNA showing log2 fold-change of> 1
with adjusted P value 0.05 (b). Altered pathways discovered using SPIA with significant changes to IL-1ß stimulation in PASMCs þ/– BMPR2
siRNA. Pathway changes to generate a heatmap indicating their activation or inhibition in each condition (c). t-SNE analysis was conducted on all
arrays mock-transfected and BMPR2 si-transfected data-points for dimensionality reduction and shows data with multiple feature correlation in
two dimensions (d). PASMC were co-transfected with Cignal NFkB reporter plasmid and NTsiRNA or BMPR2 siRNA and stimulated with BMP4
þ/– IL-1ß for 48 h (e). Results were normalized to renila expression in same plasmid and then expressed as percentage of IL-1ß treated positive
controls. Two-way ANOVA with Tukey post-test correction (*P< 0.05, **P< 0.01).
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to IL-1ß stimulation. This trend is also the case in donor
PAMSC in PDGFRA, whereas PDGFRB is increased in
mutant patient cells regardless of IL-1ß stimulation. In
AoSMC, however, loss of BMPR2 induces loss of
PDGFRa and b expression (Fig. 3e and 3f).
BMPR2 deficiency exaggerates inflammatory activation
to IL-1ß stimulation in R899Xþ/– BMPR2 transgenic
mice fed high-fat diet
To determine if these in vitro observations were relevant
in vivo, we next investigated whether IL-1ß supplementation
alters PAH phenotype in BMPR2 mutant mouse, overex-
pressing the mutation R899X in the BMPR2 gene. These
mice have been previously shown to have disrupted
BMPR2 signaling.16 In accordance with the protocol out-
lined in Fig. 4a, Rosa26-Bmpr2R899X were given IL-1ß treat-
ment. RVSP was unaffected; however, pulmonary vascular
resistance (PVR) was increased in mutant mice treated
with IL-1ß while systemic blood pressure was unaffected
(Fig. 4b). Modest increases in small pulmonary arteriole
muscularization and SMA- and PCNA-positive cells
(Fig. 4c) suggesting more advanced pulmonary vascular
remodeling were also seen. Delivery of IL-1 ß was evidenced
by the increased white blood cell (WBC) counts. Serum
levels of IL-6 were increased in mutant IL-1ß-treated
Rosa26-Bmpr2R899X animals. OPG was increased in
response to IL-1ß, regardless of mutation status (Fig. 4d).
Fig. 3. Comparison of the effect of reduced BMPR2 expression on IL-1-induced gene expression in commercial AoSMC and PASMC (a). IL-1ß
stimulation in conditions of reduced BMPR2 expression in PASMC resulted in a greater induction of IL-6 compared to normal BMPR2 expression
in PASMC but not in AoSMC or in PASMC taken from donors with and without known BMPR2 mutations (b). Expression of OPG is increased in
PASMC upon loss of BMPR2 regardless of IL-1 ß stimulation. In AoSMC, BMPR2 loss causes a decrease of OPG which was reversed by IL-1ß
stimulation; in donor cells increases were seen in OPG to IL-1ß stimulation regardless of their mutation status (c). VIPR1 expression is unaffected
by loss of BMPR2 in aortic cells; however, PASMC lacking BMPR2 show baseline increases which normalize to IL-1ß. PASMC taken from donors
display the same pattern as commercial PASMCs where loss of BMPR2 function induces a large increase in VIPR1 expression which can be
normalized to an extent by IL-1ß (d).
Array validation by qRT-PCR of receptor expression showed that expression of PDGF receptors in PASMC increased to loss of BMPR2
expression but normalized by IL-1ß; this trend is also the case in donor PAMSCs in PDGFRB, whereas PDGFRB is increased in mutant patient
cells regardless of IL-1ß stimulation. In AoSMC, however, loss of BMPR2 induces loss of PDGFRa and b expression (e, f). Ordinary one-way
ANOVA with multiple comparison by Tukey’s post-test (*P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001).
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Fig. 4. Disease model protocol for IL-1ß dosing (a). No significant changes were seen in RVSP, whereas calculated PVR shows significant increase
upon disruption of BMPR2 signaling by mutant overexpression and IL-1ß stimulation along with increases in WBC count indicating a greater
inflammatory response to IL-1ß in the mutant mice (b). Smooth muscle actin and PCNA content of the small arterioles increases with a
combination of IL-1ß increase and BMPR2 loss with representative IHC images (c). Increases in serum levels of IL-6 are seen in the IL-1ß treated
mutant mice compared to the wild-type litter-mates and serum levels of OPG display significant increase to IL-1ß regardless of mutation status
(d). Ordinary one-way ANOVA with multiple comparison by Tukey’s post-test (*P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001)
774 | BMPR2 deficiency drives differential IL-1 signaling Pickworth et al.
Discussion
Using unbiased microarray analysis, we report that IL-1ß
induces vascular bed-specific transcriptional regulation in
SMCs. Control (normal) PASMC display reduced inflam-
matory activation to IL-1ß compared with AoSMC in vitro.
mRNA and pathway analysis identified a dampened pro-
inflammatory, pro-proliferative response to IL-1ß in
PASMCs compared to AoSMC which was lost upon loss
of functional BMPR2. These findings are consistent with
reports demonstrating the beneficial effects of IL-1 receptor
antagonist (IL-1ra) in animal models of PAH where
BMPR2 is lowered, such as the monocrotaline model.9
Furthermore, we demonstrate that BMPR2 signaling dys-
function results in increased inflammatory signaling and
activation of mitogenic pathways such as PDGF, which
are inhibited in normal PASMC in vitro (Fig 5), but this
does not occur in SMCs from the systemic vascular bed.
This is an inherent part of the disease pathogenesis and
our findings could go some way to explain why patients
with BMPR2 mutations go on to develop pulmonary vas-
cular remodeling without effects on their systemic vessels.
These findings are confirmed in the cells from lung trans-
plant patients with and without disease-causing BMPR2
mutations.
We report for the first time the additive effect for the loss
of BMPR2 and administration of IL-1ß on the catalogue of
transcriptional activity. Mutant BMPR2 expression com-
bined with IL-1ß caused raised PVR associated with
increased small pulmonary vessel muscularization and cor-
related positively with serum IL-6 levels.
Therapeutic agents targeting IL-1ß are in clinical use, of
note anakinra, which has recently been trialed in therapeutic
use in PAH.18 This gives reason for further investigation
into the role IL-1ß may play in disease; late-stage clinical
trials using biologics (canukinumab)19 in cardiovascular dis-
ease gives further emphasis for insights into this potential
therapeutic area.
Our data suggest that targeting IL-1ß may be an effective
therapeutic strategy for PAH treatment and that patient
stratification according to IL-1ß responsive signals could
be useful for identifying patients with an increased likeli-
hood of treatment response. An advantage of targeting
IL-1ß specifically is that this may mitigate against the risk
of opportunistic infection by allowing other IL-1 to partici-
pate in host defence.20 Other recent research has shown that
targeting inflammatory signaling in combination with
increasing BMPR2 function is helpful in the treatment of
PAH by the use in animal models of the drug FK506
(Tacrolimus)21 and a subsequent phase IIa clinical trial.22
Manipulation of inflammatory cell infiltration and endo-
thelial cell apoptosis by antagonizing the BLT1 receptor of
leukotriene LTB4 has also been shown to be effective
in vivo,23 which backs up our findings that a combination
of inflammation and BMPR2 dysfunction is important.
Interestingly, the importance of neutrophil elastase (NE)
in the pathobiology of PAH has been well recognized,24
and recent work demonstrating NE mediated release of
IL-1ß25 may provide further evidence for a central role of
IL-1ß biology in the pathogenesis of PAH, and highlights
additional evidence for the potential use of NE inhibitors
in PAH.
Fig. 5. A schematic diagram of the pathways discussed in this paper.
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